LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Guidance from $274.300M-$278.300M to $274.800M-$276.800M vs $276.539M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 analyst estimate. Narrows FY2026 sales outlook from $274.300 million-$278.300 million to $274.800 million-$276.800
LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 analyst estimate. Narrows FY2026 sales outlook from $274.300 million-$278.300 million to $274.800 million-$276.800 million vs $276.539 million estimate.